Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23075079 | 0.89 | TDP1 (0.78) | TDP1KMT2AL3MBTL1MEN1LMNA | |
| SCHEMBL6409544 | 0.78 | TSHR (0.66) | TDP1KMT2AL3MBTL1MEN1LMNA | |
| SCHEMBL24308992 | 0.73 | PDE6D (0.55) | SMN1; SMN2POLBALDH1A1RECQL | |
| SCHEMBL6408137 | 0.73 | SIRT2 (0.69) | TDP1KMT2AL3MBTL1MEN1LMNA | |
| SCHEMBL6403089 | 0.73 | USP2 (0.67) | TDP1KMT2AL3MBTL1MEN1LMNA | |
| SCHEMBL6264446 | 0.72 | TSHR (0.64) | TDP1KMT2AL3MBTL1MEN1LMNA | |
| SCHEMBL16409989 | 0.71 | SIRT2 (1.00) | TDP1KMT2AL3MBTL1MEN1LMNA | |
| SCHEMBL22863665 | 0.71 | TLR8 (0.57) | POLBALDH1A1 | |
| SCHEMBL6403413 | 0.71 | TSHR (0.66) | TDP1KMT2AL3MBTL1MEN1LMNA | |
| SCHEMBL10647039 | 0.69 | MC4R (0.56) | L3MBTL1SMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190111028-A1 | Polymorphic Forms of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazol-3-ylthio)Acetic Acid and Uses Thereof | ARDEA BIOSCIENCES INC. | 2019-04-18 | — | — | US | disclosed |
| US-20160214947-A1 | MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | ARDEA BIOSCIENCES, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160143889-A1 | TREATMENT OF GOUT AND HYPERURICEMIA | ARDEA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9216179-B2 | Treatment of gout and hyperuricemia | ARDEA BIOSCIENCES, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130178484-A1 | TREATMENT OF GOUT AND HYPERURICEMIA | ARDEA BIOSCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214947-A1 | MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | CYP1B1, ABAT, ALDH18A1 | TDP1 3244/4885KMT2A 1303/4885L3MBTL1 4213/4885 |
| US-20160143889-A1 | TREATMENT OF GOUT AND HYPERURICEMIA | XDH, SLC10A1, URB2 | TDP1 381/4885KMT2A 3705/4885L3MBTL1 2252/4885 |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | ABCG2, ATP5ME, DNTT | TDP1 288/4885KMT2A 2263/4885L3MBTL1 2749/4885 |
| US-20190111028-A1 | Polymorphic Forms of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazol-3-ylthio)Acetic Acid and Uses Thereof | NAT1, CYP2A13, CYP4B1 | TDP1 335/4885KMT2A 3151/4885L3MBTL1 1021/4885 |
| US-20130178484-A1 | TREATMENT OF GOUT AND HYPERURICEMIA | XDH, SLC10A1, URB2 | TDP1 381/4885KMT2A 3705/4885L3MBTL1 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.